Presence of Clostridium difficile and antibiotic and beta-lactamase activities in feces of volunteers treated with oral cefixime, oral cefpodoxime proxetil, or placebo.
Three groups of six healthy adult volunteers were randomly assigned to a treatment with 400 mg of oral cefpodoxime proxetil, oral cefixime, or placebo per day for 10 days. Informed consent was obtained from all volunteers. Clostridium difficile was not detected in the feces of any subject before treatment or at any time in the subjects in the placebo group. C. difficile was, however, detected in all subjects treated with cefpodoxime proxetil and in five of six treated with cefixime. Genomic DNA restriction patterns showed that the strains of C. difficile differed from one volunteer to another. Two subjects both shed different strains at different times during the 25-day surveillance period. All isolates were resistant to cefixime and cefpodoxime (MIC for 90% of strains, 256 and 512 mg/liter, respectively). Antibiotic activity was found in the feces of one volunteer treated with cefpodoxime proxetil and of four volunteers treated with cefixime. It was inversely correlated with the presence of fecal beta-lactamase activity. Intestinal side effects were limited to modifications of stool consistency, which occurred in only 3 of the 12 treated volunteers and did not lead to cessation of treatment. These modifications were significantly associated with the presence of fecal antibiotic activity (P less than 0.05) but not with the shedding of toxigenic or nontoxigenic strains of C. difficile or with the presence of toxin A in feces, which was detected only in one perfectly healthy treated volunteer.
Chachaty
E
E
Laboratoire d'Ecologie Microbienne, Institut Gustave Roussy, Villejuif, France.
Depitre
C
C
Mario
N
N
Bourneix
C
C
Saulnier
P
P
Corthier
G
G
Andremont
A
A
D000284:Administration, Oral; D000328:Adult; D000900:Anti-Bacterial Agents / Q000493:pharmacokinetics* / Q000494:pharmacology; D001426:Bacterial Proteins; D001427:Bacterial Toxins / Q000032:analysis; D020682:Cefixime; D002439:Cefotaxime / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000494:pharmacology; D015296:Ceftizoxime / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000494:pharmacology; D002876:Chromosomes, Bacterial / Q000737:chemistry; D016360:Clostridioides difficile / Q000187:drug effects*; D004269:DNA, Bacterial / Q000378:metabolism; D004768:Enterotoxins / Q000032:analysis; D005243:Feces / Q000737:chemistry / Q000201:enzymology / Q000382:microbiology*; D006801:Humans; D011355:Prodrugs / Q000493:pharmacokinetics* / Q000494:pharmacology; D015183:Restriction Mapping; D001618:beta-Lactamases / Q000032:analysis*; D000097627:Cefpodoxime Proxetil
D000900:Anti-Bacterial Agents; D001426:Bacterial Proteins; D001427:Bacterial Toxins; D020682:Cefixime; D002439:Cefotaxime; D015296:Ceftizoxime; D004269:DNA, Bacterial; D004768:Enterotoxins; D011355:Prodrugs; D001618:beta-Lactamases; D000097627:Cefpodoxime Proxetil; C041348:tcdA protein, Clostridium difficile; C031815:toxB protein, Clostridium difficile